Neoplasms

3,817 trials 1,526 recruiting

Filter these 3,817 trials by phase, country and sponsor.

Open in Search →

NEoadjuvant Chemotherapy and Immunotherapy for a selected group of inoperable pleural Mesothelioma patients (NECIM): a feasibility study Recruiting

2023-504302-11-02 inoperable pleural mesothelioma 4 2025-07-22
CAPRI-3 Phase 3 clinical study to evaluate the use of continuing cetuximab treatment beyond first line progression in molecular selected met… Recruiting

2024-519322-20-00 metastatic colorectal cancer 5 2025-07-21
A study to investigate the safety and efficacy of SAR446523 injected subcutaneously in adult participants with relapsed/refractory myeloma Recruiting

2024-511667-28-00 Plasma cell myeloma refractory 1 2025-07-21
Phase I open-label, multi-center study to evaluate the safety, tolerability, dosimetry, and preliminary activity of [177Lu]Lu-NNS309 in pati… Recruiting

2023-510356-23-00 Locally advanced or metastatic unresectable colorectal 1 2025-07-18
Personalizing the use of pembrolizumab for patients who have a strong response in early triple negative breast cancer Recruiting

2024-515787-31-00 Patient with early triple-negative breast cancer (TNBC) 5 2025-07-18
VyClo ITCC-092 Recruiting

2023-508050-26-00 AML 3 2025-07-17
Digital monitoring of self-reported symptoms by patients treated with Cabozantinib plus Nivolumab for advanced clear-cell renal carcinoma: T… Recruiting

2024-518991-30-00 kidney cancer 6 2025-07-17
Study of Sacituzumab Govitecan Versus Standard of Care in Participants with Previously Treated Extensive Stage Small Cell Lung Cancer Recruiting

2024-515884-69-00 Extensive Stage Small Cell Lung Cancer (ES-SCLC) 5 2025-07-16
Randomized phase II trial of Cemiplimab plus OSE2101 (TEDOPI®) as maintenance therapy in ctDNA positive NSCLC. Recruiting

2024-519262-42-00 NSCLC non-small cell lung cancer 4 2025-07-15
Fecal Microbiota Transfer in Liver Cancer to Overcome Resistance to Atezolizumab/Bevacizumab – A randomized, placebo-controlled, double-blin… Recruiting

2023-506887-15-00 Hepatocellular carcinoma 4 2025-07-14
A Study to Assess safety and Effectiveness of the Inavolisib Plus a CDK4/6 Inhibitor and Letrozole Versus Placebo Plus a CDK4/6 Inhibitor an… Recruiting

2024-516162-11-00 Endocrine-Sensitive phosphatidylinositol 3-kinase (PIK3 5 2025-07-14
A Phase 1 Open-label Study to Evaluate the Safety and Efficacy of MK‑8294 Monotherapy in Advanced Solid Tumors Recruiting

2024-516870-31-00 Endometrial Carcinoma 1 2025-07-11
Bevacizumab for the treatment of cerebral RAdiation Induced NecrosiS (BRAINS) study: A multicenter, open-label, randomized clinical trial to… Recruiting

2024-512466-34-00 High grade glioma (HGG) 5 2025-07-10
Sacituzumab govitecan (SG) with bevacizumab for the treatment of brain metastases from non-small cell lung cancer (NSCLC) Recruiting

2024-514066-40-00 Patients with metastatic non-squamous NSCLC pre-treated 4 2025-07-10
Evaluation of efficacy and safety of Cemiplimab as first line treatment for advanced basal cell carcinoma (CEMI-first) - An open label, sing… Recruiting

2024-517647-31-00 basal cell carcinoma 4 2025-07-09
A phase 3, open-label, controlled, randomized study of newly diagnosed multiple myeloma treatment, designed to evaluate the efficacy and saf… Recruiting

2024-516418-39-00 Multiple Myeloma 5 2025-07-09
A Study to Assess the Adverse Events and Change in Disease Activity of Multiple Treatment Combinations with Telisotuzumab Adizutecan in Part… Recruiting

2024-512981-33-00 Metastatic Colorectal Cancer 4 2025-07-09
Clinical study to evaluate the safety of investigational medicinal product called AD-O51.4 in patients with advanced malignancies Recruiting

2024-515687-31-01 Patients suffering from cancer without further treatmen 1 2025-07-09
Neoadjuvant chemo-immunotherapy for stage III PD-L1 positive Non-Small Cell Lung Cancer (NSCLC) Recruiting

2024-519205-35-01 stage III PD-L1 positive Non-Small Cell Lung Cancer (NS 4 2025-07-08
A clinical study of sacituzumab tirumotecan with or without pembrolizumab in people with breast cancer (MK-2870-011) Recruiting

2024-516834-36-00 Locally recurrent unresectable or metastatic TNBC with 5 2025-07-08
A study to evaluate the efficacy of APG-2575 (Lisaftoclax) plus azacitidine (AZA) vs. placebo plus AZA in newly diagnosed adult subjects wit… Recruiting

2024-517247-31-00 Newly Diagnosed Higher Risk Myelodysplastic Syndrome 5 2025-07-07
Contrast-enhanced ultrasound for sentinel node detection in patients with melanoma, breast cancer or head & neck cancer Recruiting

2024-515259-40-00 breast cancer 10 2025-07-07
A Study of Nivolumab + Relatlimab Fixed-dose Combination with Chemotherapy Versus Pembrolizumab with Chemotherapy in Participants with Non-s… Recruiting

2024-513682-40-01 Non-squamous (NSQ), Stage IV or Recurrent Non-small Cel 5 2025-07-04
CLINICAL AND HUMORAL IMPACT OF PRIMARY TUMOR ABLATION IN METASTATIC RENAL CELL CARCINOMA TREATED WITH IMMUNOTHERAPY.THE ITALIC-RCC RANDOMIZE… Recruiting

2024-517789-41-00 metastatic or locally advanced renal cell carcinoma 6 2025-07-04